186 related articles for article (PubMed ID: 15030521)
1. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
2. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a new intravenous immunoglobulin preparation in primary immunodeficient patients.
Ochs HD; Lee ML; Fischer SH; Kingdon HS; Wedgwood RJ
Clin Ther; 1987; 9(5):512-22. PubMed ID: 3117369
[TBL] [Abstract][Full Text] [Related]
5. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
6. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
[TBL] [Abstract][Full Text] [Related]
9. Update on treatment of immunologic abortion with low-dose intravenous immunoglobulin.
Stricker RB; Winger EE
Am J Reprod Immunol; 2005 Dec; 54(6):390-6. PubMed ID: 16305665
[TBL] [Abstract][Full Text] [Related]
10. Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: a case report.
Barada W; Muwakkit S; Hourani R; Bitar M; Mikati M
Neuropediatrics; 2008 Apr; 39(2):131-3. PubMed ID: 18671192
[TBL] [Abstract][Full Text] [Related]
11. [Intravenous immunoglobulin therapy].
Mouthon L
Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
[TBL] [Abstract][Full Text] [Related]
12. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
13. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience.
Vo AA; Cam V; Toyoda M; Puliyanda DP; Lukovsky M; Bunnapradist S; Peng A; Yang K; Jordan SC
Clin J Am Soc Nephrol; 2006 Jul; 1(4):844-52. PubMed ID: 17699296
[TBL] [Abstract][Full Text] [Related]
14. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
[TBL] [Abstract][Full Text] [Related]
15. Neutropenia in antibody-deficient patients under IVIG replacement therapy.
Lemos S; Jacob CM; Pastorino AC; Castro AP; Fomin AB; Carneiro-Sampaio MM
Pediatr Allergy Immunol; 2009 Feb; 20(1):97-101. PubMed ID: 18373514
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin: a review.
Eibl MM; Wedgwood RJ
Immunodefic Rev; 1989; 1 Suppl():1-42. PubMed ID: 2698646
[TBL] [Abstract][Full Text] [Related]
17. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
[TBL] [Abstract][Full Text] [Related]
19. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
Matamoros N; De Gracia J; Hernández F; Pons J; Alvarez A; Jiménez V
Int Immunopharmacol; 2005 Mar; 5(3):619-26. PubMed ID: 15683857
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
